AstraZeneca launches US$1.5B restructuring programme to fund pipeline growth through 2029
AstraZeneca plans to reinvest most of the savings in research and development, although the programme is expected to incur up to US$2 billion in one-time restructuring costs over three years.
USA – AstraZeneca has launched a three-year restructuring programme to generate US$1.5 billion in annual savings by 2029, as the pharmaceutical company seeks to protect growth and strengthen its drug development pipeline amid mounting patent expirations.
The initiative, called Reshaping for Sustainable Growth, was announced during the company’s third-quarter 2026 earnings update.
AstraZeneca plans to reinvest most of the savings in research and development, although the programme is expected to incur up to US$2 billion in one-time restructuring costs over three years.
The move follows similar cost-cutting programmes at Pfizer, Bristol Myers Squibb, Merck, Novo Nordisk and GSK, as major pharmaceutical companies seek to manage operating costs while replenishing their pipelines.
Pipeline investment takes priority over acquisitions
Chief Executive Officer Pascal Soriot reiterated the company’s target of achieving US$80 billion in annual revenue by 2030, saying AstraZeneca has the scientific capabilities, medicines in development and workforce to deliver that growth without a major acquisition.
However, the company remains open to transactions that strengthen its therapeutic franchises and expand its portfolio.
Reports of a potential combination with Bristol Myers Squibb had recently fuelled speculation about AstraZeneca’s acquisition strategy, although the proposed deal did not materialise.
The restructuring will involve shifting resources between research programmes, business functions and geographic markets.
Chief Financial Officer Aradhana Sarin said the changes would eliminate some positions but create new roles elsewhere, with no expected net reduction in the company’s workforce.
AstraZeneca’s employment base has expanded in recent years, making it one of three large pharmaceutical companies to consistently increase its workforce since 2021, according to a Fierce Pharma report.
Its previous major cost-reduction programme began in 2016, when the cholesterol drug Crestor lost patent protection.
Patent expirations increase pressure on revenue
The latest restructuring comes as several established AstraZeneca medicines face generic and biosimilar competition.
Farxiga, its SGLT2 inhibitor for diabetes, heart failure and chronic kidney disease, has already encountered generic competition in the US and China.
Global third-quarter sales fell 25% year on year to approximately US$1.6 billion.
Other products, including Brilinta, Lynparza and Symbicort, have also lost market exclusivity in some territories.
Further patent expirations are expected in the early 2030s for major oncology medicines such as Calquence, Tagrisso and Imfinzi.
To offset these pressures, Soriot highlighted 23 major clinical readouts expected in 2027, representing more than US$20 billion in potential peak annual sales.
These include Phase III results for Datroway, an antibody-drug conjugate developed with Daiichi Sankyo, and Etcamah, an oral selective oestrogen receptor degrader being investigated for adjuvant breast cancer.
Twelve pipeline programmes have individual non-risk-adjusted peak sales potential exceeding US$5 billion, Soriot said.
Partnerships and China investment face regulatory uncertainty
AstraZeneca has also completed a US$2 billion equity investment in Summit Therapeutics as part of a broader collaboration to combine its antibody-drug conjugate platform with ivonescimab, a PD-1/VEGF bispecific antibody developed by Summit’s partner Akeso.
The partnership aims to explore combination treatments for cancer, potentially expanding the clinical applications of both companies’ technologies.
However, proposed regulatory changes in China and the US could affect future cross-border biotechnology investments.
China is considering restrictions on foreign acquisitions involving certain advanced biotechnology platforms, while the US Treasury Department has proposed expanding investment restrictions under the COINS Act to cover selected pharmaceutical investments in China.
Soriot said AstraZeneca was monitoring the proposals and would comply with any regulations that take effect.
He also stressed the importance of international scientific collaboration, noting that medicines licensed from Chinese developers could be manufactured and commercialised in the US to serve American patients.
Be the first to leave a comment